Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
1998-12-13
2009-08-25
Lukton, David (Department: 1654)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C530S331000
Reexamination Certificate
active
07579323
ABSTRACT:
This invention provides analogs of hemiasterlin, methods of synthesis of the analogs and use of the analogs as cytotoxic and anti-mitotic agents.
REFERENCES:
patent: 4048305 (1977-09-01), Molteni et al.
patent: 5661175 (1997-08-01), Kashman
patent: 5736517 (1998-04-01), Bogden
patent: 6126939 (2000-10-01), Eisenbach-Schwartz et al.
patent: 6153590 (2000-11-01), Andersen et al.
patent: 6194578 (2001-02-01), Griffith et al.
patent: 6214799 (2001-04-01), Webber
patent: 6331554 (2001-12-01), Dragovich
patent: 6362166 (2002-03-01), Webber
patent: 0 150 227 (1985-08-01), None
patent: 1 002 802 (2004-12-01), None
patent: 216551 (1989-09-01), None
patent: 224706 (1990-07-01), None
patent: 96/33211 (1996-10-01), None
patent: 97/04004 (1997-02-01), None
Reetz , Angew. Chem., Int. Ed. Engl., 31(12), 1626-9, 1992).
Falender (Biocatalysis and Biotransformation 13(2), 131-139, 1995.
Chang, L. L. (Bioorganic & Medicinal Chemistry Letters 2(10), 1207-12, 1992).
Baldwin, Jack E. (J. Chem. Soc., Chem. Comm. (16), 1280-1, 1986).
Tetrahedron (1995), 51(39), 10653-62 CODEN; TETRAB; ISSN: 0040-4020, Sep. 25, 1995, Colman et al., “Cytotoxic peptides from the marine sponge Cymbastela sp.”
Journal of Organic Chemistry, vol. 59, No. 11, Jun. 3, 1994, P. Crews et al, “Milnamide A., an Unusual Cytotoxic Tripeptide from the Marine Sponge Auletta cf. Constricta”.
Journal of Organic Chemistry, vol. 52, No. 14, Jul. 10, 1987, pp. 3091-3093, Chan et al, “Stereostructures of Geodiamolides A and B, Novel Cyclodepsipeptides from the Marine Sponge Geodia s.p.”
Experimental Hematology, vol. 23, No. 7, Jul. 1995, pp. 583-587, Fabian et al., “Growth modulation and differentiation af acute myeloid leukemia cells by jaspamide”.
Talpir R. et al. Tetrahedron Lett. (1994) 35:4453-4456.
Anderson RJ. et al. Tetrahedron Letters (1997) 38(3):317-320.
Anderson HJ. et al. Cancer Chemother Pharmacol (1997) 39:223-226.
Coleman JE. et al. Acta Cryst. (1996) C51:1525-11527.
Evans D.A. et al. J. Am. Chem. Soc. (1990) 112:4011-4030.
Evans D.A. et al. Tetrahedron (1988) 44:5525-5540.
Frérot E. et al. Tetrahedron (1991) 47:259-270.
Hoffman A. J. Am. Chem. Soc. (1929) 51:2542-2547.
Dragovich, Peter S. et al., “Structure-Based Design, Synthesis, and Biological Evaluation of Irreversible Human Rhinovirus 3C Protease Inhibitors. 2. Peptide Structure—Activity Studies”,J. Med. Chem.41: 2819-2834 (1998).
Leftheris, Katerina, “Development of Highly Potent Inhibitors of Ras Famesyltransferase Possessing Cellular and In Vivo Activity”,J. Med. Chem.39: 224-236 (1996).
Skehan, P. et al. New Colorimetric Cytotoxicity Assay for Anticancer-Drug Screening, Journal of National Cancer Institute vol. 82, No. 13, pp. 1107-1112, 1990.
Andersen Raymond
Coleman John
Nieman James
Piers Edward
Roberge Michel
Arent & Fox LLP
Lukton David
The University of British Columbia
LandOfFree
Hemiasterlin analogs does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Hemiasterlin analogs, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Hemiasterlin analogs will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4131349